LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc.

LENZ·NASDAQ

$7.13

-0.14%
HealthcareBiotechnology

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

At a Glance

Live Snapshot
Market Cap$223.56M
EPS-2.8500
P/E Ratio-5.61
Earnings Date07/29/2026

lenz

Accounts Receivables

Last Annual Value

329.00K

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Competitors Analysis of Accounts Receivables

LENZ · NASDAQ
CompanyAccounts Receivables
CAGR 3Y
CAGR 5Y
CAGR 10Y
329.00K
N/AN/AN/A 
SVRA logo
Savara Inc.
NASDAQ:SVRA
0.00
N/AN/AN/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
0.00
N/AN/AN/A
25.35M
N/AN/AN/A
1.45M
-6.6%10.0%18.1%
36.99M
N/A83.8%N/A
25.50M
-22.4%-26.3%N/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Fair Value Envelope

LENZ · NASDAQ

Our analysis suggests that LENZ has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.13, this represents a potential HIDDEN relative to our calculated worth for LENZ Therapeutics, Inc..

Intrinsic Value
Current Price: $7.13